Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Research Funding"

The Tortured Path to the Cortisone Discovery

Thomas R. Collins  |  February 17, 2019

CHICAGO—The path to the discovery of cortisone—a top-selling, important drug, with dozens of indications—was complicated by failure, false moves, desperation and obsession. The tale, recounted in the Philip Hench, MD, Memorial Lecture: Crossroads of History & Hope: Discovery & First Use of Cortisone for RA at the 2018 ACR/ARHP Annual Meeting in October, is an…

The Non-Linear Path of Discovery, & Publicly Funded Research

Philip Seo, MD, MHS  |  November 19, 2018

Black powder was initially developed in 9th century China, by Taoists searching for the philosopher’s stone, which fans of Harry Potter will remember is the talisman that grants eternal life. The Chinese name for black powder literally translates as fire medicine. The chemical composition of black powder was first recorded in China during the 11th…

Rheumatology Research Foundation Announces Grant Recipients

From the College  |  July 19, 2018

On July 1, the Rheumatology Research Foundation awarded grants to a wide range of rheumatology trainees and professionals. The recipients will receive funding for essential education and training, as well as innovative research projects. Their applications were closely examined by experts in different areas of the field to ensure awards went to the most promising…

Funding Available for Community Practitioners from the Rheumatology Research Foundation

From the College  |  May 17, 2018

Few opportunities exist for rheumatologists in community-based practice who, in addition to taking care of patients, want to test their own observations through research. Limited funding, time constraints and competition from larger academic medical centers are some of the barriers hindering clinical research in this setting. The Rheumatology Research Foundation is addressing this issue with…

ACR Offers Hands-On 101 Course in Advocacy

Kathy Holliman  |  July 5, 2017

The ACR’s Advocacy 101 course will be held Sept. 24 in Washington, D.C. The course is an interactive, intensive, full-day opportunity for fellows in training and program directors to learn about and become inspired to advocate for the continued strength of rheumatology recruitment and support for education, research and clinical practice. Course applications will be…

GSK, Astra, J&J Link with Universities in New Drug Research Fund

Reuters Staff  |  January 26, 2016

LONDON (Reuters)—GlaxoSmithKline, AstraZeneca and Johnson & Johnson have joined with three leading British universities to create a new 40 million pounds ($57 million) fund backing early drug research. The Apollo Therapeutics Fund, which aims to improve the speed and potential of university research being translated into new medicines, is a further example of a trend…

U.S. House Passes Bill to Speed New Drugs to Market

Reuters Staff  |  July 15, 2015

WASHINGTON (Reuters)—The U.S. House of Representatives on Friday passed a bill aimed at speeding new drugs to the market after lawmakers defeated last-minute amendments that threatened to derail it. The House voted 344 to 77 in favor of the bill, known as the 21st Century Cures Act, which would require the FDA to streamline the…

Tight NIH Budget Makes Research Careers Tough

Richard Quinn  |  June 13, 2013

Lack of research funding a challenge for researchers, especially those early in their careers.  (posted June 13, 2013)

Sequester Affects Rheumatologists on Two Fronts—Medicare Reimbursement and Research Funding

Richard Quinn  |  April 18, 2013

Rheumatologists are already feeling two effects from Congress’ inability to solve sequestration: a 2% reduction in Medicare reimbursements and slashed funding for research financed by the National Institutes of Health.

New Lupus Insight Prize Aims to Advance Lupus Research

Dawn Antoline  |  July 2, 2012

The Lupus Insight Prize will provide $200,000 to one researcher to help fund a project dedicated to furthering understanding of the genetic, environmental, molecular, immunologic, or cellular aspects of lupus or its treatment.

  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences